GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Duopharma Biotech Bhd (XKLS:7148) » Definitions » Debt-to-Revenue

Duopharma Biotech Bhd (XKLS:7148) Debt-to-Revenue : 0.87 (As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Duopharma Biotech Bhd Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Duopharma Biotech Bhd's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was RM227.2 Mil. Duopharma Biotech Bhd's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was RM362.7 Mil. Duopharma Biotech Bhd's annualized Revenue for the quarter that ended in Sep. 2023 was RM676.9 Mil. Duopharma Biotech Bhd's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 was 0.87.


Duopharma Biotech Bhd Debt-to-Revenue Historical Data

The historical data trend for Duopharma Biotech Bhd's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Duopharma Biotech Bhd Debt-to-Revenue Chart

Duopharma Biotech Bhd Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.46 0.53 0.63 0.62

Duopharma Biotech Bhd Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.71 0.54 0.65 0.87

Competitive Comparison of Duopharma Biotech Bhd's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Debt-to-Revenue falls into.



Duopharma Biotech Bhd Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Duopharma Biotech Bhd's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(135.081 + 296.522) / 696.717
=0.62

Duopharma Biotech Bhd's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(227.154 + 362.677) / 676.94
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2023) Revenue data.


Duopharma Biotech Bhd Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Duopharma Biotech Bhd's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Duopharma Biotech Bhd (XKLS:7148) Business Description

Traded in Other Exchanges
N/A
Address
Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines.

Duopharma Biotech Bhd (XKLS:7148) Headlines

No Headlines